REDWOOD CITY, Calif., May 15, 2019 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), along with researchers from leading academic institutions and pharmaceutical companies, will present 27 abstracts at the ASCO Annual Meeting detailing new insights into precision oncology generated from its commercially available Guardant360 and GuardantOMNI assays, as well as its research-use-only (RUO) LUNAR liquid biopsy.
For patients with advanced cancer, these include multiple investigations of the GuardantOMNI assay’s ability to identify patients who may benefit from treatment with immunotherapy. Additionally, researchers will present Guardant360 data to demonstrate the effectiveness of new targeted drugs, as well as the feasibility of serial ctDNA analysis to rapidly predict treatment response and long-term clinical benefit.
For patients with early stage disease, the presentations include an analytical validation of Guardant’s LUNAR assay (Abstract 3057), as well as a pilot study exploring the LUNAR assay’s ability to identify early-stage colorectal cancer patients who may benefit from adjuvant therapy after undergoing an intervention with curative intent (Abstract 3602). This is a particularly challenging clinical setting for the detection of circulating tumor DNA in blood because patients who have undergone curative-intent interventions typically have little-to-no evidence of disease, and very low residual tumor DNA shedding in circulation.
“Guardant is committed to expanding the benefits of precision oncology across the continuum of care,” said Guardant Health Chief Medical Officer Dr. Richard Lanman. “The new insights we and our research partners will bring to ASCO this year continue to demonstrate the many advantages of blood-based genomic testing over tissue-based genomic testing in support of a blood-first paradigm in early stage and late stage cancer.”
Guardant’s data will be featured in the following presentations at ASCO this year:
|Abstract Title||Date||Time||Abstract Number|
|Analytical validation of a tumor-agnostic integrated multi-analyte|
circulating tumor DNA (ctDNA) assay in early stage cancer
|8 a.m. - 11 a.m.||3057|
|Dynamic monitoring of circulating tumor DNA next-generation gene|
sequencing as a predictive biomarker of response and progression free
survival after pembrolizumab monotherapy in patients with advanced NSCLC.
|8 a.m. - 11 a.m.||3040|
|Molecular biology and treatment strategies for non-V600 BRAF-mutant|
|8 a.m. - 11 a.m.||3102|
|Molecular circulating tumor DNA response to identify long-term survival in|
patients receiving immunotherapy with initial radiologic stable disease
|8 a.m. - 11 a.m.||2546|
|Comprehensive genomic profiling of circulating cell-free DNA (cfDNA)|
distinguishes focal amplification (amp) from aneuploidy among MET amps
in diverse advanced cancer types
|8 a.m. - 11 a.m.||3046|
|Baseline cfDNA characteristics and evolution of cfDNA profile during|
treatment with selective FGFR inhibitor TAS-120
|6/1 ||8 a.m. - 11 a.m.||3056|
|Identification of genomic alterations by circulating tumor DNA in|
leiomyosarcoma: A molecular analysis of 73 patients
|8 a.m. - 11 a.m.||11044|
|TiFFANY study: A multicenter phase II basket-type clinical trial to evaluate|
efficacy and safety of pan-FGFR inhibitor TAS-120 for advanced solid
malignancies with FGFR alterations identified by circulating tumor DNA
|8 a.m. - 11 a.m.||TPS3156|
|Profiling of genomic alterations in MAPK/ERK signaling in a large cohort of|
metastatic prostate cancer (mPC) patients
|1:15 p.m. - 4:15 p.m.||5032|
|Genomic landscape of metastatic hormone sensitive prostate cancer|
(mHSPC) vs. metastatic castration-refractory prostate cancer (mCRPC) by
circulating tumor DNA (ctDNA).
|1:15 p.m. - 4:15 p.m||5043|
|AR changes in circulating-tumor DNA (ctDNA) in patients with metastatic|
castration-resistant prostate cancer (mCRPC) treated with high-dose
|1:15 p.m. - 4:15 p.m||5058|
|Blood tumor mutational burden (bTMB) and tumor PD-L1 as predictive|
biomarkers of survival in MYSTIC: First-line durvalumab (D) ±
tremelimumab (T) versus chemotherapy (CT) in metastatic (m) NSCLC.
|8 a.m. - 11 a.m.||9016|
|Early circulating tumor (ct)DNA dynamics and efficacy of lorlatinib|
in patients (pts) with advanced ALK-positive non-small cell lung cancer
|8 a.m. - 11 a.m.||9019|
|Longitudinal Analysis of Plasma ALK Mutations During Treatment with|
Next-Generation ALK Inhibitors.
|8 a.m. - 11 a.m.||9068|
|Tracking plasma KRAS mutations (m) in lung adenocarcinoma (LUAC)|
|8 a.m. - 11 a.m.||9055|
|A plasma-only integrated somatic and epigenomic circulating tumor DNA|
(ctDNA) assay to inform recurrence risk in colorectal cancer (CRC).
|8 a.m. - 11 a.m.||3602|
|Updated analysis and impact of plasma-detected microsatellite stability|
(MSS) and tumor mutation burden (TMB) in a phase II trial of durvalumab
(D) plus tremelimumab (T) and best supportive care (BSC) versus BSC
alone in patients (pts) with refractory metastatic colorectal carcinoma
|8 a.m. - 11 a.m.|
|Blood-Based Genomic Profiling of cell-free DNA (OMNI) to Identify|
Microsatellite Instability, tumor mutational burden and Wnt/B-Catenin
Pathway Alterations in Patients with Gastrointestinal Tract Cancers
|8 a.m. - 11 a.m.|
|Identifying anti-EGFR (EGFRi) response subgroups using evidence of ctDNA|
|8 a.m. - 11 a.m.||3587|
|Genomic alterations after EGFR blockade in patients with RAS wild-type|
metastatic colorectal cancer: Combined tissue and blood-based analysis
from SCRUM-Japan GI-SCREEN and GOZILA
|8 a.m. - 11 a.m.||3528|
|Association between gene fusions and anti-EGFR resistance signature in|
|8 a.m. - 11 a.m.||3564|
|Prediction model for detecting Circulating tumor DNA (ctDNA) in|
Metastatic Colorectal Cancer (mCRC).
|8 a.m. - 11 a.m.||3590|
|A Landscape of Circulating Tumor DNA in Esophageal Adenocarcinoma and|
Squamous Cell Carcinoma.
|8 a.m. - 11 a.m.||4070|
|Blood-Based Next-Generation Sequencing Analysis of Neuroendocrine|
|8 a.m. - 11 a.m.||4110|
|Circulating tumor DNA dynamics, serial testing and evolution on treatment|
in 322 colorectal cancer patients.
|8 a.m. - 11 a.m.||3566|
|Genomic testing and treatment landscape in patients (pts) with advanced|
non-small cell lung cancer (aNSCLC) using real-world data from community
|1:15 p.m. - 4:15 p.m.||1585|
|Correlation of circulating tumor DNA (ctDNA), tissue-based genomic|
profiling and clinical efficacy in the biomarker directed Ph1b trial in
metastatic bladder cancer (BISCAY).
|1:15 p.m. - 4:15 p.m.||4553|
About Guardant Health
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Its Guardant Health Oncology Platform is designed to leverage its capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs. In pursuit of its goal to manage cancer across all stages of the disease, Guardant Health has launched multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for advanced stage cancer patients, which fuel its LUNAR development programs for recurrence and early detection. Since its launch in 2014, Guardant360 has been used by more than 6,000 oncologists, over 50 biopharmaceutical companies and all 28 of the National Comprehensive Cancer Network centers.
This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the expected impact of data to be presented at upcoming scientific congresses. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. Additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2018 and in its other reports filed with the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.
Lynn Lewis or Carrie Mendivil
Josh Wein or Ian Stone
© 2019 Canjex Publishing Ltd. All rights reserved.